Biogen's portfolio and research efforts in multiple sclerosis: an interview with Dr Ralph Kern.

Neurodegener Dis Manag

Worldwide Medical, Biogen, Cambridge, MA, USA.

Published: February 2017

Ralph Kern speaks to Laura Dormer, Commissioning Editor: Dr Ralph Kern is Senior Vice President and Head of Worldwide Medical at Biogen in Cambridge, MA, USA. In this role, he oversees Biogen's global therapeutic, regional and country medical teams, global medical operations, as well as medical research and scientific communications functions. Prior to joining Biogen, he was head of the Neuroscience Medical Unit at Novartis Pharmaceuticals Corporation and held various medical and commercial leadership roles at Genzyme Corporation. Prior to joining industry, he was a consultant neurologist at Mount Sinai Hospital and the University Health Network in Toronto, Ontario and was head of the neurology postgraduate academic program at the University of Toronto. Ralph completed neurology postgraduate training at McGill University and completed a masters of health administration from the Institute for Health Policy, Management and Evaluation at the University of Toronto. He is a member of the College of Physicians and Surgeons of Ontario and the Royal College of Physicians and Surgeons of Canada.

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2016-0061DOI Listing

Publication Analysis

Top Keywords

ralph kern
12
prior joining
8
neurology postgraduate
8
university toronto
8
college physicians
8
physicians surgeons
8
medical
6
biogen's portfolio
4
portfolio efforts
4
efforts multiple
4

Similar Publications

Objective: To examine the impact of 40Hz gamma stimulation on the preservation of the corpus callosum, a critical structure for interhemispheric connectivity, in people with mild cognitive impairment or Alzheimer's disease.

Methods: OVERTURE (NCT03556280) participants were randomized 2:1 (Active:Sham) to receive daily, 1-h, 40Hz gamma sensory stimulation or sham treatment for 6 months. Structural magnetic resonance imaging data were analyzed to assess changes in corpus callosum area ( = 50; 33 for active, 17 for sham).

View Article and Find Full Text PDF

: There is a lack of evidence regarding the impact of time loss, match exposure, and age at injury on career progression in elite football. Therefore, the aim of this study was to identify injury characteristics and their influence on career progression in a German youth academy. : During the 2012/2013 season, a prospective cohort study reported 107 time-loss injuries among 130 young athletes from an elite German soccer academy.

View Article and Find Full Text PDF

Background: Little is known about age-related changes in injury characteristics and burden, and existing data are inconsistent, highlighting the need for new studies on this topic. This study aimed to describe age-related injury risk, severity and burden in a German elite youth football academy.

Methods: A prospective cohort study was conducted in the 2012/2013 season, reporting 109 time-loss injuries among 138 young athletes playing at an elite football academy in Germany.

View Article and Find Full Text PDF
Article Synopsis
  • This study looked at how a treatment called debamestrocel affects special substances in the body (biomarkers) in people with ALS, a disease that affects muscles.
  • They tested 196 people, some got the treatment while others got a fake treatment (placebo) and checked their cerebrospinal fluid (CSF) for 45 different biomarkers.
  • Results showed that debamestrocel improved many of these biomarkers, which could mean it's helping to protect nerves and reduce inflammation, especially in patients with more advanced ALS.
View Article and Find Full Text PDF

Background: Alzheimer's Disease (AD) is a multifactorial, progressive neurodegenerative disease that disrupts synaptic and neuronal activity and network oscillations. It is characterized by neuronal loss, brain atrophy and a decline in cognitive and functional abilities. Cognito's Evoked Gamma Therapy System provides an innovative approach for AD by inducing EEG-verified gamma oscillations through sensory stimulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!